On September 23, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled "A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies (Press release, MEI Pharma, SEP 23, 2019, View Source [SID1234539702])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agenda will include an in-depth review of the PI3K pathway, an overview of the B-cell malignancy treatment landscape, and an update on the MEI Pharma pipeline with a focus on ME-401, a differentiated inhibitor of PI3Kδ.

The event will also feature key opinion leaders in PI3K inhibition and the treatment of B-cell malignancies, including guest speakers:

Lewis C. Cantley, Ph.D.
Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, Professor of Cancer Biology in Medicine
Nishitha M. Reddy, M.D., M.B.B.S.
Associate Professor of Medicine at Vanderbilt University Medical Center
Matthew J. Matasar, M.D.
Medical Director, Memorial Sloan Kettering Bergen
Webcast Information
You can access the live webcast under the investor relations section of MEI’s website on the "Events and Presentation" page at: www.meipharma.com. A replay of the webcast will be archived for at least 30 days after the conclusion of the live event.